Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP28 | Q96RU2 | 1/20 | 0.50 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | CCR5 | P51681 | 3/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 6/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18892489 | 0.90 | LMNA (0.53) | USP28USP25HTTCCR5PTGER1 | |
| SCHEMBL16307117 | 0.84 | LMNA (0.44) | HTTLMNAALDH1A1RAB9AMTNR1A | |
| SCHEMBL16307127 | 0.82 | LMNA (0.37) | HTTLMNAALDH1A1MTNR1B | |
| SCHEMBL16293551 | 0.82 | PTGER1 (0.46) | USP28USP25HTTCCR5PTGER1 | |
| SCHEMBL4855734 | 0.80 | CCR5 (0.47) | USP28USP25HTTCCR5PTGER1 | |
| SCHEMBL27696917 | 0.80 | CCR5 (0.47) | USP28USP25HTTCCR5PTGER1 | |
| SCHEMBL16294070 | 0.78 | TAAR1 (0.49) | RAB9A | |
| SCHEMBL3416114 | 0.76 | USP28 (0.61) | USP28USP25HTTCCR5PTGER1 | |
| SCHEMBL11335547 | 0.75 | USP28 (0.54) | USP28USP25HTTCCR5PTGER1 | |
| SCHEMBL16293563 | 0.74 | CCR5 (0.57) | USP28USP25HTTCCR5PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | USP28 4603/4885USP25 3920/4885HTT 4402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.